You just read:

Affinium Pharmaceuticals Announces Positive Efficacy, Safety, and Tolerability Results from Phase 2a Clinical Trial of Oral AFN-1252 in Acute Bacterial Skin & Skin Structure Infections

News provided by

Affinium Pharmaceuticals

21 Mar, 2013, 04:37 GMT